Neoadjuvant Chemotherapy and Perioperative Complications Associated with Pulmonary Toxicity.
- 1Department of Anesthesiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, 212001, People's Republic of China.
Abstract
Purpose
Neoadjuvant chemotherapy (NAC) is widely used in multimodal cancer treatment and can improve surgical conditions and patient prognosis. However, NAC-related pulmonary toxicity may impair respiratory function and warrants attention during perioperative risk assessment.Methods
This narrative review summarizes evidence on chemotherapy-associated pulmonary toxicity, focusing on underlying mechanisms, clinical characteristics, diagnostic strategies, and perioperative anesthetic management. Direct clinical evidence from patients receiving NAC is distinguished from findings in other treatment settings and experimental models.Results
Several chemotherapeutic agents, including bleomycin, methotrexate, taxanes, gemcitabine, and cisplatin, as well as selected targeted therapies, have been associated with drug-induced lung injury, often presenting as interstitial lung disease. Clinical and experimental evidence implicates mitochondrial dysfunction, oxidative stress, immune-mediated injury, inflammatory activation, and alveolar-capillary barrier disruption. Advanced age, pre-existing lung disease, reduced diffusing capacity, metabolic abnormalities, smoking history, and multi-agent treatment may indicate increased susceptibility, although their relevance varies by drug and treatment setting. Evidence from broader perioperative settings and experimental models suggests that mechanical ventilation, excessive oxygen exposure, and surgical stress may aggravate existing pulmonary injury.Conclusion
NAC-related pulmonary toxicity merits consideration in perioperative assessment, but direct evidence linking it to perioperative outcomes remains limited. Pulmonary function testing and clinically indicated imaging can inform individualized risk assessment. Lung-protective ventilation, appropriate oxygen therapy, individualized anesthetic management, and postoperative respiratory support draw largely on evidence from other populations; their effectiveness specifically in patients with NAC-related pulmonary injury requires further evaluation.
Related
- Bridging the Artificial Intelligence Translation Gap in Perioperative Pulmonary and Respiratory Complications: A Practical Framework for Institution-Level Implementation
- Tumor Clusterin Expression at Diagnosis Is Associated with Residual Disease Burden After Neoadjuvant Chemotherapy in Breast Cancer
- Impact of perioperative physical exercise on postoperative pulmonary complications in patients undergoing cardiac surgery: a systematic review and meta-analysis
- Single-cell and spatial transcriptomics reveal a DLL4-associated tip-like endothelial niche linked to neoadjuvant chemotherapy non-response in muscle-invasive bladder cancer.
- Perioperative diabetes related complications in patients undergoing major surgery are associated with the duration of gastrointestinal and orthopaedic surgery.
BibTeX
@article{chen2026neoadjuvant,
title = {{Neoadjuvant Chemotherapy and Perioperative Complications Associated with Pulmonary Toxicity.}},
author = {Kefan Chen and Han Gu and Haoran Qian and Zibang He and Peng Jiang and Longbin Zheng},
journal = {Drug design, development and therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s631444},
url = {https://europepmc.org/article/MED/42960132},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Neoadjuvant Chemotherapy and Perioperative Complications Associated with Pulmonary Toxicity.
AU - Kefan Chen
AU - Han Gu
AU - Haoran Qian
AU - Zibang He
AU - Peng Jiang
AU - Longbin Zheng
PY - 2026
DA - 2026/10/25
JO - Drug design, development and therapy
DO - 10.2147/dddt.s631444
UR - https://europepmc.org/article/MED/42960132
AB - Purpose Neoadjuvant chemotherapy (NAC) is widely used in multimodal cancer treatment and can improve surgical conditions and patient prognosis. However, NAC-related pulmonary toxicity may impair respiratory function and warrants attention during perioperative risk assessment.Methods This narrative review summarizes evidence on chemotherapy-associated pulmonary toxicity, focusing on underlying mechanisms, clinical characteristics, diagnostic strategies, and perioperative anesthetic management. Direct clinical evidence from patients receiving NAC is distinguished from findings in other treatment settings and experimental models.Results Several chemotherapeutic agents, including bleomycin, methotrexate, taxanes, gemcitabine, and cisplatin, as well as selected targeted therapies, have been associated with drug-induced lung injury, often presenting as interstitial lung disease. Clinical and experimental evidence implicates mitochondrial dysfunction, oxidative stress, immune-mediated injury, inflammatory activation, and alveolar-capillary barrier disruption. Advanced age, pre-existing lung disease, reduced diffusing capacity, metabolic abnormalities, smoking history, and multi-agent treatment may indicate increased susceptibility, although their relevance varies by drug and treatment setting. Evidence from broader perioperative settings and experimental models suggests that mechanical ventilation, excessive oxygen exposure, and surgical stress may aggravate existing pulmonary injury.Conclusion NAC-related pulmonary toxicity merits consideration in perioperative assessment, but direct evidence linking it to perioperative outcomes remains limited. Pulmonary function testing and clinically indicated imaging can inform individualized risk assessment. Lung-protective ventilation, appropriate oxygen therapy, individualized anesthetic management, and postoperative respiratory support draw largely on evidence from other populations; their effectiveness specifically in patients with NAC-related pulmonary injury requires further evaluation.
SN - 1177-8881
ER -